Achieve Life Sciences Inc Financials

ACHV

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Achieve Life Sciences Inc (ACHV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Achieve Life Sciences Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.75x

For every $1 of reported earnings, Achieve Life Sciences Inc generates $0.75 in operating cash flow (-$29.8M OCF vs -$39.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$39.8M

YoY-33.6%

Achieve Life Sciences Inc reported -$39.8M in net income in fiscal year 2024. This represents a decrease of 33.6% from the prior year.

EPS (Diluted)

$-1.24

YoY+17.3%

Achieve Life Sciences Inc earned $-1.24 per diluted share (EPS) in fiscal year 2024. This represents an increase of 17.3% from the prior year.

Cash & Debt

$12.8M

YoY-18.0%

5Y CAGR-5.2%

10Y CAGR-7.5%

Achieve Life Sciences Inc held $12.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

35M

YoY+63.9%

Achieve Life Sciences Inc had 35M shares outstanding in fiscal year 2024. This represents an increase of 63.9% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$22.8M

YoY+44.3%

5Y CAGR+18.7%

10Y CAGR-6.8%

Achieve Life Sciences Inc invested $22.8M in research and development in fiscal year 2024. This represents an increase of 44.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ACHV Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$22.8M+44.3%	$15.8M-47.4%	$30.1M+25.5%	$24.0M+248.2%	$6.9M-28.9%	$9.7M
SG&A Expenses	$16.3M+42.1%	$11.4M+6.7%	$10.7M+17.5%	$9.1M+16.0%	$7.9M+14.8%	$6.9M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$2.2M-23.6%	$2.9M+59.5%	$1.8M	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$39.8M-33.6%	-$29.8M+29.6%	-$42.4M-27.7%	-$33.2M-125.1%	-$14.7M+10.2%	-$16.4M
EPS (Diluted)	$-1.24+17.3%	$-1.50+62.5%	$-4.00+2.0%	$-4.08+24.7%	$-5.42	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'24	Q3'24	Q3'24	Q3'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.3M-20.7%	$6.7M-5.5%	$7.1M+302.6%	$1.8M-76.8%	$7.6M+48.8%	$5.1M+82.7%	$2.8M+30.0%	$2.2M
SG&A Expenses	$9.4M+60.0%	$5.9M+1.0%	$5.8M+300.9%	$1.4M-70.2%	$4.9M+46.4%	$3.3M+4.2%	$3.2M+95.4%	$1.6M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$192K+0.5%	$191K+3.2%	$185K	N/A	$366K-54.5%	$804K-1.1%	$813K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$14.4M-13.5%	-$12.7M+0.8%	-$12.8M-301.6%	-$3.2M+74.5%	-$12.5M-47.9%	-$8.5M-30.3%	-$6.5M-73.6%	-$3.7M
EPS (Diluted)	$-0.28+24.3%	$-0.370.0%	$-0.37	N/A	$-0.36-44.0%	$-0.25+3.8%	$-0.26	N/A

ACHV Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$38.6M+99.4%	$19.4M-35.4%	$30.0M-36.9%	$47.5M+17.9%	$40.3M+91.2%	$21.1M
Current Assets	$36.5M+114.7%	$17.0M-37.9%	$27.3M-38.7%	$44.6M+20.6%	$37.0M+113.3%	$17.3M
Cash & Equivalents	$12.8M-18.0%	$15.5M-37.2%	$24.8M-42.4%	$43.0M+20.0%	$35.9M+115.2%	$16.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$8K
Goodwill	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M
Total Liabilities	$17.7M-14.8%	$20.8M-3.9%	$21.7M+11.3%	$19.5M+546.5%	$3.0M-0.5%	$3.0M
Current Liabilities	$6.7M-67.9%	$20.8M-3.6%	$21.6M+374.7%	$4.5M+55.0%	$2.9M+2.3%	$2.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$20.9M+1543.3%	-$1.4M-117.4%	$8.3M-70.4%	$28.0M-24.8%	$37.3M+106.6%	$18.1M
Retained Earnings	-$205.6M-24.0%	-$165.8M-21.9%	-$135.9M-45.3%	-$93.6M-54.9%	-$60.4M-32.2%	-$45.7M

Metric	Q3'25	Q3'25	Q3'25	Q3'24	Q3'24	Q3'24	Q3'24	Q4'23
Total Assets	$52.0M-11.7%	$58.9M+115.4%	$27.4M-29.2%	$38.6M-19.4%	$47.9M-26.0%	$64.8M-7.5%	$70.0M+261.5%	$19.4M
Current Assets	$50.1M-12.0%	$56.9M+127.6%	$25.0M-31.4%	$36.5M-19.9%	$45.5M-27.2%	$62.5M-7.7%	$67.7M+298.7%	$17.0M
Cash & Equivalents	$31.9M-38.4%	$51.9M+298.5%	$13.0M+2.1%	$12.8M+33.6%	$9.5M-35.3%	$14.8M-77.8%	$66.4M+327.1%	$15.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$4.8M-2.5%	$5.0M-42.5%	$8.6M+107525.0%	$8K-99.9%	$9.9M+54.1%	$6.4M+24.9%	$5.2M+57188.9%	$9K
Goodwill	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M0.0%	$1.0M
Total Liabilities	$18.4M+6.7%	$17.3M+1.1%	$17.1M-3.7%	$17.7M+7.2%	$16.5M-26.5%	$22.5M+9.4%	$20.6M-1.2%	$20.8M
Current Liabilities	$9.7M+13.5%	$8.6M+20.2%	$7.1M+6.7%	$6.7M-0.5%	$6.7M-51.0%	$13.7M-33.4%	$20.6M-1.2%	$20.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$33.6M-19.3%	$41.7M+305.4%	$10.3M-50.8%	$20.9M-33.4%	$31.4M-25.8%	$42.3M-14.5%	$49.5M+3515.5%	-$1.4M
Retained Earnings	-$245.6M-6.2%	-$231.1M-5.8%	-$218.4M-6.2%	-$205.6M-6.4%	-$193.2M-6.9%	-$180.7M-4.9%	-$172.2M-3.9%	-$165.8M

ACHV Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$29.8M-21.6%	-$24.5M+34.8%	-$37.6M-27.6%	-$29.4M-118.5%	-$13.5M+11.4%	-$15.2M
Capital Expenditures	N/A	$21K	N/A	N/A	$17K-67.9%	$53K
Free Cash Flow	N/A	-$24.5M	N/A	N/A	-$13.5M+11.6%	-$15.3M
Investing Cash Flow	-$21.6M-102661.9%	-$21K	N/A	N/A	-$17K-100.3%	$5.0M
Financing Cash Flow	$48.5M+217.6%	$15.3M-20.9%	$19.3M-47.2%	$36.6M+12.0%	$32.7M+88.6%	$17.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'24	Q3'24	Q3'24	Q3'24	Q4'23
Operating Cash Flow	-$11.3M-24.9%	-$9.1M+18.2%	-$11.1M-20.7%	-$9.2M+11.4%	-$10.4M-110.8%	-$4.9M+6.9%	-$5.3M-21.2%	-$4.4M
Capital Expenditures	$13K-78.3%	$60K+757.1%	$7K+600.0%	$1K	$0+100.0%	-$2K-103.7%	$54K+800.0%	$6K
Free Cash Flow	-$5.8M-94.2%	-$3.0M-74.9%	-$1.7M+50.2%	-$3.4M-11.2%	-$3.1M+20.1%	-$3.8M+22.3%	-$4.9M-13.1%	-$4.4M
Investing Cash Flow	-$12.7M-288.8%	$6.7M-41.0%	$11.4M-3.1%	$11.7M-11.7%	$13.3M+465.4%	$2.3M-12.8%	$2.7M+44933.3%	-$6K
Financing Cash Flow	$4.0M	N/A	N/A	$682K+108.4%	-$8.1M-5202.0%	-$153K-100.3%	$56.1M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ACHV Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-103.1%+50.8pp	-153.9%-12.6pp	-141.3%-71.5pp	-69.8%-33.2pp	-36.5%+41.2pp	-77.8%
Current Ratio	5.46+4.6	0.82-0.4	1.27-8.5	9.80-2.8	12.60+6.6	6.04
Debt-to-Equity	0.85+15.2	-14.38-17.0	2.61+1.9	0.69+0.6	0.08-0.1	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'24	Q3'24	Q3'24	Q3'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-27.8%-6.2pp	-21.6%+25.3pp	-46.9%-31.7pp	-15.2%+11.0pp	-26.1%-13.1pp	-13.1%-3.8pp	-9.3%+28.5pp	-37.8%
Current Ratio	5.14-1.5	6.64+3.1	3.51-2.0	5.46-1.3	6.78+2.2	4.56+1.3	3.29+2.5	0.82
Debt-to-Equity	0.55+0.1	0.41-1.2	1.66+0.8	0.85+0.3	0.530.0	0.53+0.1	0.42+14.8	-14.38
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Nuvectis Pharma, Inc. NVCT

$224.1M

Milestone Pharmaceuticals MIST

$144.8M

Alpha Cognition ACOG

$127.2M

Coherus CHRS

$197.0M

Eledon Pharmaceuticals Inc ELDN

$174.4M

Frequently Asked Questions

Is Achieve Life Sciences Inc profitable?

No, Achieve Life Sciences Inc (ACHV) reported a net income of -$39.8M in fiscal year 2024.

What is Achieve Life Sciences Inc's earnings per share (EPS)?

Achieve Life Sciences Inc (ACHV) reported diluted earnings per share of $-1.24 for fiscal year 2024. This represents a 17.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Achieve Life Sciences Inc's operating cash flow?

Achieve Life Sciences Inc (ACHV) generated -$29.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Achieve Life Sciences Inc's total assets?

Achieve Life Sciences Inc (ACHV) had $38.6M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Achieve Life Sciences Inc spend on research and development?

Achieve Life Sciences Inc (ACHV) invested $22.8M in research and development during fiscal year 2024.

How many shares does Achieve Life Sciences Inc have outstanding?

Achieve Life Sciences Inc (ACHV) had 35M shares outstanding as of fiscal year 2024.

What is Achieve Life Sciences Inc's current ratio?

Achieve Life Sciences Inc (ACHV) had a current ratio of 5.46 as of fiscal year 2024, which is generally considered healthy.

What is Achieve Life Sciences Inc's debt-to-equity ratio?

Achieve Life Sciences Inc (ACHV) had a debt-to-equity ratio of 0.85 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Achieve Life Sciences Inc's return on assets (ROA)?

Achieve Life Sciences Inc (ACHV) had a return on assets of -103.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Achieve Life Sciences Inc's cash runway?

Based on fiscal year 2024 data, Achieve Life Sciences Inc (ACHV) had $12.8M in cash against an annual operating cash burn of $29.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Achieve Life Sciences Inc's Piotroski F-Score?

Achieve Life Sciences Inc (ACHV) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Achieve Life Sciences Inc's earnings high quality?

Achieve Life Sciences Inc (ACHV) has an earnings quality ratio of 0.75x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.